Evidence map›Paper›PMID 35930226›Full record

ArticleAdvances in experimental medicine and biology2022

Molecular Features Triggered by Antipsychotic Medication in Brain Cells.

Lívia Ramos-da-Silva, André S L M Antunes

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lívia Ramos-da-SilvaLaboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, State University of Campinas (UNICAMP), Campinas, SP, Brazil. l172407@dac.unicamp.br.
André S L M AntunesBrazilian Biosciences National Laboratory (LNBio), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treating schizophrenia is a challenge currently handled with the use of antipsychotic drugs. Despite being the most applied treatment strategy, current antipsychotics present severe limitations and side effects which impact patients' health and quality of life. For instance, although these drugs target mainly the dopamine system, they present target promiscuity and work by distinct mechanisms of action. As a consequence, complete comprehension of their pharmacological properties remains elusive. This chapter highlights research from the past 5 years that contributed to our current understanding of the mechanism of action and molecular features triggered by antipsychotic drugs in brain cells. In addition, we briefly discuss potential new therapeutic targets and strategies to treat schizophrenia.

Indexed as

Antipsychotic AgentsSchizophreniaBrainDopamineHumansQuality of LifeAntipsychotic AgentsDopamineAntipsychotic drugsCellular targetsMolecular targetsSchizophrenia

Identifiers

PMID35930226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.